Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PACERONE vs QUINIDEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Life-threatening recurrent ventricular arrhythmias (e.g., ventricular fibrillation, hemodynamically unstable ventricular tachycardia),Atrial fibrillation and atrial flutter (off-label may include maintenance of sinus rhythm)
Conversion and prevention of atrial fibrillation/flutter,Maintenance of sinus rhythm after cardioversion,Treatment of ventricular arrhythmias (off-label)
Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
Biphasic: initial 3-10 days; terminal elimination half-life 40-58 days (mean ~53 days) due to extensive tissue distribution and slow release from fat. Clinical context: steady-state achieved in 2-4 months without loading dose.
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
Primarily hepatic via CYP3A4 and CYP2C8; active metabolite desethylamiodarone; substrate of P-glycoprotein.
Primarily hepatic via CYP3A4 (major) and CYP2C9 (minor) to active metabolites (3-hydroxyquinidine, quinidine-N-oxide); also renal excretion of unchanged drug (20%).
Primarily hepatic metabolism (CYP3A4, CYP2C8) to desethylamiodarone (active). Renal elimination of drug and metabolites: <1% of unchanged drug; ~40% of dose as metabolites. Fecal elimination: ~70% of dose as metabolites, with some parent drug.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
96% bound, primarily to albumin and beta-lipoproteins.
80-90% bound to plasma proteins: primarily albumin and alpha-1-acid glycoprotein.
66 L/kg (range 10-200 L/kg) indicating extensive tissue distribution, especially in adipose tissue, liver, and lungs.
2-4 L/kg; extensive tissue distribution with high affinity for myocardium (tissue-to-plasma ratio >10).
Oral: 30-80% (mean ~50%), increased by food; erratic absorption due to high lipophilicity. IV: 100%.
70-80% for immediate-release oral; 50-70% for sustained-release formulations due to first-pass metabolism; absorption reduced by food.
No specific GFR-based dose adjustment required; caution in severe renal impairment due to possible accumulation of active metabolite desethylamiodarone. Monitor serum levels and QT interval.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours. Cr Cl 10-29 m L/min: administer 50% of normal dose every 8 hours. Cr Cl <10 m L/min: administer 50% of normal dose every 12 hours.
Contraindicated in severe hepatic disease (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce maintenance dose by 50% and monitor liver function. Mild impairment (Child-Pugh A): no adjustment, but monitor.
Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose by 50%; monitor levels. Child-Pugh class C: contraindicated or use with extreme caution; reduce dose by 75% with therapeutic drug monitoring.
Loading: 10-20 mg/kg/day PO in divided doses for 7-10 days; maintenance: 5-10 mg/kg/day PO once daily. IV loading: 5 mg/kg over 30 min, then 5-15 mg/kg/day continuous infusion.
Oral: 15-60 mg/kg/day in 4-5 divided doses; maximum single dose 600 mg. For chronic suppression: start 30 mg/kg/day in 4-5 divided doses.
Lower maintenance doses (100-200 mg/day PO) due to increased risk of bradycardia, QT prolongation, and thyroid dysfunction. Monitor renal function and electrolytes closely.
Start at lower end of dosing range (200 mg every 8 hours) due to decreased hepatic and renal function; adjust based on plasma levels and QT interval monitoring.
Only for patients with life-threatening arrhythmias due to risk of pulmonary toxicity, hepatotoxicity, and proarrhythmia; requires baseline and periodic monitoring of pulmonary function, liver enzymes, thyroid function, and ECG.
Increased mortality in treatment of non-life-threatening ventricular arrhythmias; proarrhythmic effects (torsades de pointes).
Pulmonary toxicity (interstitial pneumonitis, pulmonary fibrosis), hepatotoxicity (elevated liver enzymes, hepatic failure), proarrhythmia (worsening arrhythmias, torsades de pointes), thyroid dysfunction (hypo- or hyperthyroidism), optic neuropathy/neuritis, skin discoloration, photosensitivity, bradycardia, and drug interactions (CYP450 and P-gp mediated).
Proarrhythmia (torsades de pointes), hepatotoxicity, cinchonism, hypersensitivity reactions, worsening of heart failure, digitalis toxicity, incomplete AV block, electrolyte disturbances.
Cardiogenic shock, severe sinus node dysfunction (without pacemaker), second- or third-degree AV block (without pacemaker), marked bradycardia, and hypersensitivity to amiodarone or iodine.
Hypersensitivity to quinidine or cinchona alkaloids, complete AV block or severe intraventricular conduction defects, myasthenia gravis, history of thrombocytopenia with quinidine, concurrent use with drugs that prolong QT interval (unless absolutely necessary).
Avoid grapefruit juice as it inhibits CYP3A4 and can increase amiodarone levels. St. John's wort may decrease amiodarone efficacy by inducing metabolism. Take with food to reduce gastrointestinal irritation.
Grapefruit juice increases quinidine bioavailability and serum levels, raising toxicity risk. Avoid grapefruit and grapefruit juice. Alkaline foods (e.g., antacids, milk) may increase quinidine absorption. High-sodium diet may enhance potassium loss and worsen arrhythmias. Avoid excessive caffeine or stimulants.
Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine content. Second and third trimesters: continued risk of fetal hypothyroidism and bradycardia; neonatal monitoring for thyroid function and ECG is recommended.
First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal QT prolongation, neonatal thrombocytopenia, and tachycardia. Fetal distress may occur. Avoid if alternative exists, but if needed, monitor fetal ECG and heart rate.
Amiodarone is excreted into breast milk with an M/P ratio of approximately 0.1-1.0. Due to significant accumulation in infant tissues and long half-life, breastfeeding is contraindicated because of potential for neonatal hypothyroidism and bradycardia.
Quinidine is excreted into breast milk. M/P ratio reported as 0.57–0.78. Amount is low, but monitor infant for arrhythmias, bruising, and bleeding. Generally considered compatible with breastfeeding if maternal monitoring is done.
Pregnancy increases volume of distribution and clearance of amiodarone, potentially requiring dose adjustments to maintain therapeutic levels. However, due to risks, use is limited to severe arrhythmias and doses should be minimized. Monitoring of serum levels is recommended to guide dosing.
Increased volume of distribution may require dose increases. Protein binding decreases, potentially lowering total drug concentrations. Monitor free drug levels if possible. adjust dose based on therapeutic drug monitoring and clinical response. Close monitoring recommended.
Amiodarone has an extremely long half-life (up to 107 days) causing delayed onset and prolonged effects. Monitor for thyroid dysfunction, pulmonary fibrosis, liver toxicity, and corneal deposits. Avoid coadministration with drugs prolonging QT interval. Use lowest effective dose due to cumulative toxicity.
Quinidine (as Quinidex) is a class Ia antiarrhythmic; monitor QRS and QT intervals due to risk of torsades de pointes. It also has anticholinergic properties, causing diarrhea in up to 50% of patients, which can be dose-limiting. Drug interactions are critical: quinidine inhibits CYP2D6, increasing levels of digoxin, warfarin, and many beta-blockers. Consider checking serum quinidine levels (therapeutic: 2-6 mcg/m L) and ECG if initiating or adjusting dose.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations.,Inform your doctor if you experience vision changes, thyroid symptoms (weight change, heat/cold intolerance), or skin discoloration.,Avoid grapefruit juice and St. John's wort as they may affect drug levels.,Use sun protection; amiodarone increases sun sensitivity.,Do not breastfeed while taking this medication.,Keep all follow-up appointments for blood tests, eye exams, and lung function tests.,This medication can cause birth defects; use effective contraception.
Take exactly as prescribed; do not double dose if missed.,Avoid grapefruit juice as it can increase quinidine levels and toxicity.,Report new or worsening palpitations, dizziness, syncope, or irregular heartbeat immediately.,May cause diarrhea; contact your prescriber if diarrhea becomes severe or persistent.,Quinidine can cause blurred vision, tinnitus, or headache; report these to your doctor.,Avoid over-the-counter medications without consulting your doctor (especially antacids, antihistamines, and cold remedies).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PACERONE vs QUINIDEX, answered by our medical review team.
PACERONE is a Antiarrhythmic Agent that works by Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.. QUINIDEX is a Antiarrhythmic Agent that works by Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PACERONE and QUINIDEX depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PACERONE is: Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.. The standard adult dose of QUINIDEX is: Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PACERONE and QUINIDEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PACERONE is classified as Category C. Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine conte. QUINIDEX is classified as Category C. First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal Q. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.